Zetomipzomib maleate is under clinical development by Kezar Life Sciences and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase II drugs for Systemic Lupus Erythematosus have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zetomipzomib maleate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zetomipzomib maleate overview

Zetomipzomib maleate is under development for the treatment of systemic lupus erythematosus with or without lupus nephritis, autoimmune hepatitis and idiopathic inflammatory myopathy including dermatomyositis and polymyositis. It is administered by subcutaneous and intravenous route of administration. The drug candidate is an analog of ONX 0914 and acts by targeting immunoproteasome LMP7. It was also under development for acquired (autoimmune) hemolytic anemia, immune thrombocytopenic purpura.

Kezar Life Sciences overview

Kezar Life Sciences is a clinical-stage biotechnology company. It discovers and develops small molecule therapies to treat autoimmunity and cancer. The company offers products such as KZR-616 and KZR-261. It is involved in the treatment of various autoimmune diseases, lupus nephritis, solid tumors, oncology, immunology and idiopathic inflammatory myopathies. Kezar Life Sciences’ product KZR-616 is a selective immunoproteasome inhibitor used for the treatment of chronic immune-mediated diseases. The company also discovers and develops targeted cancer and immuno-oncology indications using its protein secretion pathway research platform. Kezar Life Sciences is headquartered in South San Francisco, California, the US.

For a complete picture of Zetomipzomib maleate’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.